Over ninety percent of End Stage Renal Disease (ESRD) patients suffer from anemia due to insufficient endogenous production of human erythropoietin. Until the advent of Recombinant Human Erythropoietin (r-HuEPO) over 30 years ago, patients with ESRD were treated mainly with multiple blood transfusions. The high cost of r-HuEPO in addition to the narrow margin between an effective do-sage and toxicity in drug administration calls for optimal dosage strategy capable of minimizing cost and toxicity while at the same time achieving the desired do-sage outcome. It is well known from control theory that a controller can be de-signed for any plant provided there is readily available a valid model for such a plant. We present Robust Identification procedure, a dimensionality reduction technique capable of capturing the inherent dynamics of anemia patients; conse-quently producing individualized model suitable for robust control synthesis and any other controller design methodologies.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.